Tracleer Webpage Draws FDA Warning Letter For Superiority, Efficacy Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
Actelion webpage also failed to include any risk information for the pulmonary arterial hypertension therapy, FDA ad division says.